We then analyzed the tumor volumes on the left (A549) and right (A549-CXCL13) sides and found that EGFR-CXCR5-CAR-T was more effective in eradicating A549-CXCL13 (right-side tumor) than classical EGFR-CAR-T (Figure 5B). The gene discussed is CXCL13; the disease is neoplasm.